Aemetis Reports Third Quarter 2026 Financial Results

Aemetis reported third-quarter 2026 revenue of $88.2 million, up $29.0 million (49%) year over year, and RNG sales volume rose 39% to 158,200 MMBtu. Operating income was $20.9 million, net income was $5.2 million ($0.07 per basic share), and adjusted EBITDA was $24.8 million; each improved by roughly $29 million versus the prior-year quarter. Results included $24.7 million of Section 45Z tax-credit income, including an approximately $11.0 million cumulative first-half 2026 true-up, while two digesters began operating in October, bringing the network to 14 digesters serving 17 dairies.

Analysis

The key issue is earnings quality, not the headline growth rate. Section 45Z income is almost equal to reported adjusted EBITDA, and the disclosed $11.0 million cumulative true-up is a timing benefit rather than evidence of a repeatable quarterly run rate. Before underwriting the result, verify whether the credit income is included in adjusted EBITDA, how much was recognized versus collected in cash, and what portion of the quarter’s improvement remains after removing the true-up. The 39% volume increase is more durable evidence of operating progress, but it does not by itself establish attractive unit economics.

Near term, the market may reward the strong reported result; that reaction is vulnerable if investors treat credit-supported earnings as recurring. Over 1–3 months, watch the next filing for credit cash conversion, RNG realized pricing, operating cash flow, and digester ramp data. The two digesters added after quarter-end offer upside to future volume, but commissioning and utilization may lag capacity. Over 6–18 months, 45Z methodology, eligibility, and policy durability remain material to the earnings profile; a reversal or adverse interpretation could overwhelm incremental volume growth.

Contrarian read: the result is neither clean proof of a structural profit inflection nor dismissible as purely a tax-credit artifact. The operating-volume trend is constructive, but the credit concentration and absent cash-conversion detail argue against chasing the print. No reliable valuation or balance-sheet data here supports a price target or high-conviction directional trade.

Key Decisions for Investors

• Do not chase AMTX solely on the earnings headline. Treat the reported improvement as provisional until the company clarifies 45Z treatment within adjusted EBITDA and discloses cash receipts or receivables associated with the credits.
• Set a 1–3 month diligence trigger: reassess after the next filing or update on operating cash flow, credit realization, RNG pricing, and utilization of the newly operating digesters. Better cash conversion with continued volume growth would strengthen the long case.
• Keep AMTX on a policy-risk watchlist. A change to 45Z eligibility or the applicable model that reduces expected credit value would falsify the constructive thesis; sustained volume growth and improving cash generation despite lower credit contribution would strengthen it.
• Without valuation, liquidity, and balance-sheet detail, avoid a directional position or options trade based on this release alone.